Growing support for you and your patients.
Norditropin® is committed to providing helpful tools to support your practice and your patients.
The FlexPro® Pen
The FlexPro® pen is easy to use, with 4 strengths and 160 dose options1 for a closer match to your patient’s prescribed doses. This may lead to:
- Fewer pens used each month
- Fewer double injections
Use the Pen Selector to help you choose the right pen combination for your patient, and see how many equal a 30-day supply.a
aAll unused Norditropin® products must be refrigerated (36°F to 46°F) prior to first use. Do not freeze and avoid direct light. After first injection, Norditropin® pens can either be stored outside of the refrigerator (up to 77°F) for use within 3 weeks, or in the refrigerator (between 36°F and 46°F) for use within 4 weeks.
Dosing Quick Reference
Please click here for Prescribing Information.
Indications and Usage
Norditropin® (somatropin) injection is indicated for the treatment of pediatric patients with:
- growth failure due to inadequate secretion of endogenous growth hormone (GH)
- short stature associated with Noonan syndrome,
- short stature associated with Turner syndrome,
- short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years of age
- Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range
- growth failure due to Prader-Willi syndrome (PWS)
Norditropin® is also indicated for the replacement of endogenous GH in adults with growth hormone deficiency (GHD)
Dosage and Administration
Norditropin® should be administered subcutaneously (2).
- Pediatric GHD: 0.17 mg/kg/week to 0.24 mg/kg/week (0.024 to 0.034 mg/kg/day)
- Noonan Syndrome: Up to 0.46 mg/kg/week (up to 0.066 mg/kg/day)
- Turner Syndrome: Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
- SGA: Up to 0.47 mg/kg/ week (up to 0.067 mg/kg/day)
- Idiopathic Short Stature: Up to 0.47 mg/kg/week (up to 0.067 mg/kg/day)
- Prader-Willi Syndrome: 0.24 mg/kg/week (0.034 mg/ kg/day)
- Adult GHD: 0.004 mg/kg/day to be increased as tolerated to not more than 0.016 mg/kg/day after approximately 6 weeks, or a starting dose of approximately 0.2 mg/day (range, 0.15 to 0.30 mg/day) increased gradually every 1 to 2 months by increments of approximately 0.1 to 0.2 mg/day (2.2)
- Injection sites should always be rotated to avoid lipoatrophy (2.3)
We designed NordiCare.com to provide a way for you to stay up to date with the status of your patients, communicate with your case managers, and submit NordiCare® paperwork online.Register for NordiCare.com
- Fuchs GS, Mikkelsen S, Knudsen TK, Kappelgaard A-M. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. Clin Ther. 2009;31(12):2906-2914.